IL116325D0 - Substituted 1h-imidazoles their preparation and use - Google Patents
Substituted 1h-imidazoles their preparation and useInfo
- Publication number
- IL116325D0 IL116325D0 IL11632595A IL11632595A IL116325D0 IL 116325 D0 IL116325 D0 IL 116325D0 IL 11632595 A IL11632595 A IL 11632595A IL 11632595 A IL11632595 A IL 11632595A IL 116325 D0 IL116325 D0 IL 116325D0
- Authority
- IL
- Israel
- Prior art keywords
- imidazoles
- substituted
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical class data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9425211.1A GB9425211D0 (en) | 1994-12-14 | 1994-12-14 | Substituted 1H-imidazoles |
Publications (2)
Publication Number | Publication Date |
---|---|
IL116325D0 true IL116325D0 (en) | 1996-03-31 |
IL116325A IL116325A (en) | 1999-10-28 |
Family
ID=10765918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11632595A IL116325A (en) | 1994-12-14 | 1995-12-11 | Substituted 4-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazoles and substituted 4-(2,3-dihydro-1h-inden-1-yl)-1h-imidazoles the optically active isomers thereof and racemic mixtures thereof their preparation and pharmaceutical compositions containing them |
Country Status (26)
Country | Link |
---|---|
US (1) | US5658938A (en) |
EP (1) | EP0717037A1 (en) |
JP (1) | JPH08208622A (en) |
KR (1) | KR960022474A (en) |
CN (1) | CN1054376C (en) |
AR (1) | AR002257A1 (en) |
AU (1) | AU693614B2 (en) |
BG (1) | BG63043B1 (en) |
BR (1) | BR9505815A (en) |
CA (1) | CA2165133A1 (en) |
CZ (1) | CZ327195A3 (en) |
EE (1) | EE9500064A (en) |
FI (1) | FI955927A (en) |
GB (1) | GB9425211D0 (en) |
HU (1) | HUT73980A (en) |
IL (1) | IL116325A (en) |
IS (1) | IS4311A (en) |
MX (1) | MX9505063A (en) |
NO (1) | NO305316B1 (en) |
NZ (1) | NZ280646A (en) |
PL (1) | PL311736A1 (en) |
RO (1) | RO113346B1 (en) |
RU (1) | RU2156239C2 (en) |
SK (1) | SK155095A3 (en) |
TW (1) | TW303362B (en) |
ZA (1) | ZA9510554B (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
ZA9801080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
US20030073850A1 (en) * | 1998-08-07 | 2003-04-17 | Altenbach Robert J. | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use |
US6503935B1 (en) | 1998-08-07 | 2003-01-07 | Abbott Laboratories | Imidazoles and related compounds as α1A agonists |
US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
WO2001085698A1 (en) | 2000-05-08 | 2001-11-15 | Orion Corporation | New polycyclic indanylimidazoles with alpha2 adrenergic activity |
TW200306783A (en) * | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
FI20022007A0 (en) * | 2002-11-08 | 2002-11-08 | Juvantia Pharma Ltd Oy | Oromucosal preparation and method of preparation thereof |
FI20022159A0 (en) * | 2002-12-05 | 2002-12-05 | Orion Corp | New pharmaceutical compounds |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
CN101374517A (en) * | 2006-01-27 | 2009-02-25 | 弗·哈夫曼-拉罗切有限公司 | Use of 2-imidazoles for the treatment of CNS disorders |
KR101172940B1 (en) * | 2006-10-19 | 2012-08-10 | 에프. 호프만-라 로슈 아게 | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
CN101528710B (en) * | 2006-10-19 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | Aminomethyl-4-imidazoles |
CN101535292A (en) * | 2006-11-02 | 2009-09-16 | 弗·哈夫曼-拉罗切有限公司 | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
CA2669112A1 (en) * | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
AU2007332641A1 (en) * | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR) |
US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
AU2008209860A1 (en) | 2007-02-02 | 2008-08-07 | F. Hoffmann-La Roche Ag | Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders |
CA2678072A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
JP2010518161A (en) * | 2007-02-13 | 2010-05-27 | シェーリング コーポレイションSchering Corporation | Chroman derivatives and analogs as function selective α2C adrenergic receptor agonists |
RU2009134059A (en) * | 2007-02-13 | 2011-03-20 | Шеринг Корпорейшн (US) | Functionally selective alpha2c adrenoreceptor agonists |
KR101335845B1 (en) * | 2007-02-15 | 2013-12-02 | 에프. 호프만-라 로슈 아게 | 2-aminooxazolines as taar1 ligands |
BRPI0812840A2 (en) | 2007-07-02 | 2014-12-09 | Hoffmann La Roche | 2-immedazolins |
KR101150628B1 (en) * | 2007-07-03 | 2012-05-31 | 에프. 호프만-라 로슈 아게 | 4-imidazolines and their use as antidepressants |
AU2008281918A1 (en) * | 2007-07-27 | 2009-02-05 | F. Hoffmann-La Roche Ag | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands |
AU2008281877A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of CNS disorders |
CN101784515A (en) * | 2007-08-03 | 2010-07-21 | 弗·哈夫曼-拉罗切有限公司 | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
CL2008003553A1 (en) * | 2007-12-05 | 2009-11-27 | Grindeks Jsc | Process to prepare atipamezole or 5- (2-ethyl-2,3-dihydro-1h-inden-2-yl) -1h-imidazole hydrochloride: and the intermediate compounds considered in the process |
US8383818B2 (en) | 2008-02-21 | 2013-02-26 | Merck Sharp & Dohme Corp. | Functionally selective alpha2C adrenoreceptor agonists |
US8242153B2 (en) * | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
EP2321287B1 (en) * | 2008-07-24 | 2015-11-11 | F. Hoffmann-La Roche AG | 4,5-dihydro-oxazol-2-yl derivatives |
US20110190247A1 (en) * | 2008-08-04 | 2011-08-04 | Schering Corporation | Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
AR073628A1 (en) | 2008-10-07 | 2010-11-17 | Schering Corp | Analogs of biaryl spiroaminooxazoline and spiroaminodiazoline modulators of alpha2c adrenergic receptors, pharmaceutical compositions comprising them and their use in allergic rhinitis, cardiac disorders and other diseases |
US20100311798A1 (en) * | 2009-06-05 | 2010-12-09 | Decoret Guillaume | 2-aminooxazolines as taar1 ligands |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US8673950B2 (en) | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
ES2554843T3 (en) | 2012-01-12 | 2015-12-23 | F. Hoffmann-La Roche Ag | Heterocyclic derivatives as associated amine trace receptors (TAARs) |
AU2013314388B2 (en) | 2012-09-14 | 2016-07-14 | F. Hoffmann-La Roche Ag | Pyrazole carboxamide derivatives as TAAR modulators for use in the treatment of several disorders, such as depression, diabetes and Parkinson's disease |
RU2637938C2 (en) | 2012-09-17 | 2017-12-08 | Ф. Хоффманн-Ля Рош Аг | Triazolcarboxamide derivatives |
WO2015165085A1 (en) | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
MX2016016488A (en) | 2014-08-27 | 2017-03-30 | F Hoffmann-La Roche Ag | Substituted azetidine derivatives as taar ligands. |
EP3186250B1 (en) | 2014-08-27 | 2018-04-18 | F.Hoffmann-La Roche Ag | Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders |
SI3430010T1 (en) | 2016-03-17 | 2020-10-30 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0374216B2 (en) * | 1983-08-25 | 1991-11-26 | ||
GB2167408B (en) * | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
GB8626287D0 (en) * | 1986-11-04 | 1986-12-03 | Ucb Sa | Substituted 1h-imidazoles |
GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
US5151526A (en) * | 1990-10-11 | 1992-09-29 | The United States Of America As Represented By The Secretary Of The Army | 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic |
JPH04210680A (en) * | 1990-12-01 | 1992-07-31 | Nissan Chem Ind Ltd | Imidazole derivative and plant growth regulator |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
-
1994
- 1994-12-14 GB GBGB9425211.1A patent/GB9425211D0/en active Pending
-
1995
- 1995-12-05 MX MX9505063A patent/MX9505063A/en not_active IP Right Cessation
- 1995-12-08 RO RO95-02138A patent/RO113346B1/en unknown
- 1995-12-08 TW TW084113098A patent/TW303362B/zh active
- 1995-12-08 BG BG100208A patent/BG63043B1/en unknown
- 1995-12-08 PL PL95311736A patent/PL311736A1/en unknown
- 1995-12-08 IS IS4311A patent/IS4311A/en unknown
- 1995-12-08 US US08/569,947 patent/US5658938A/en not_active Expired - Fee Related
- 1995-12-11 NZ NZ280646A patent/NZ280646A/en unknown
- 1995-12-11 IL IL11632595A patent/IL116325A/en not_active IP Right Cessation
- 1995-12-11 SK SK1550-95A patent/SK155095A3/en unknown
- 1995-12-11 FI FI955927A patent/FI955927A/en unknown
- 1995-12-12 HU HU9503549A patent/HUT73980A/en unknown
- 1995-12-12 AR ARP950100512A patent/AR002257A1/en unknown
- 1995-12-12 CZ CZ953271A patent/CZ327195A3/en unknown
- 1995-12-12 CN CN95120834A patent/CN1054376C/en not_active IP Right Cessation
- 1995-12-12 ZA ZA9510554A patent/ZA9510554B/en unknown
- 1995-12-12 EE EE9500064A patent/EE9500064A/en unknown
- 1995-12-12 AU AU40368/95A patent/AU693614B2/en not_active Ceased
- 1995-12-12 NO NO955034A patent/NO305316B1/en not_active IP Right Cessation
- 1995-12-13 CA CA002165133A patent/CA2165133A1/en not_active Abandoned
- 1995-12-13 BR BR9505815A patent/BR9505815A/en not_active Application Discontinuation
- 1995-12-13 EP EP95870132A patent/EP0717037A1/en not_active Withdrawn
- 1995-12-13 JP JP7324502A patent/JPH08208622A/en active Pending
- 1995-12-13 RU RU95120582/04A patent/RU2156239C2/en active
- 1995-12-14 KR KR1019950049572A patent/KR960022474A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EE9500064A (en) | 1996-06-17 |
KR960022474A (en) | 1996-07-18 |
IL116325A (en) | 1999-10-28 |
CN1133837A (en) | 1996-10-23 |
AU693614B2 (en) | 1998-07-02 |
IS4311A (en) | 1996-06-15 |
CN1054376C (en) | 2000-07-12 |
CZ327195A3 (en) | 1996-07-17 |
NO305316B1 (en) | 1999-05-10 |
SK155095A3 (en) | 1997-02-05 |
AU4036895A (en) | 1996-06-20 |
MX9505063A (en) | 1997-01-31 |
CA2165133A1 (en) | 1996-06-15 |
JPH08208622A (en) | 1996-08-13 |
NO955034L (en) | 1996-06-17 |
FI955927D0 (en) | |
BG63043B1 (en) | 2001-02-28 |
ZA9510554B (en) | 1996-06-13 |
PL311736A1 (en) | 1996-06-24 |
RU2156239C2 (en) | 2000-09-20 |
GB9425211D0 (en) | 1995-02-15 |
NO955034D0 (en) | 1995-12-12 |
NZ280646A (en) | 1996-08-27 |
HUT73980A (en) | 1996-10-28 |
HU9503549D0 (en) | 1996-02-28 |
EP0717037A1 (en) | 1996-06-19 |
FI955927A (en) | 1996-06-15 |
BG100208A (en) | 1996-07-31 |
FI955927A0 (en) | 1995-12-11 |
TW303362B (en) | 1997-04-21 |
RO113346B1 (en) | 1998-06-30 |
AR002257A1 (en) | 1998-03-11 |
US5658938A (en) | 1997-08-19 |
BR9505815A (en) | 1998-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0710667A3 (en) | Modified oligonucleotides, their preparation and their use | |
HUT77052A (en) | Fungicide and insekticide composition, preparation and use thereof | |
EP0738149A4 (en) | 1-aminoindan derivatives and compositions thereof | |
ZA9405720B (en) | Electrode and preparation thereof | |
PL324890A1 (en) | Halogenbenzimidazoles and their application as microbicides | |
IL122428D0 (en) | Minizymes and minribozymes and uses thereof | |
HU0000369A3 (en) | 3-thiocarbamoylpyrazole derivatives and their use as pesticides | |
ZA9307081B (en) | Azaquinoxalines processes for their preparation and their use | |
PL328822A1 (en) | Human bikinine | |
AU5752398A (en) | Novel ketobenzamides and their use | |
GB9415125D0 (en) | Surgical product and its use | |
GB9624927D0 (en) | Gels and their use | |
HK1038365A1 (en) | L-ribavirin and uses thereof | |
EP1032377A4 (en) | Substituted 2-aminoacetamides and the use thereof | |
HRP970349B1 (en) | Sulfonamides and their use | |
EP1021185A4 (en) | Didhydropyrimidines and uses thereof | |
IL115239D0 (en) | Dentifrice compositions and their preparation | |
ZA9400711B (en) | Heterocyclic compounds and their preparation and use | |
ZA9503419B (en) | Anglostatin and method and use | |
BR9509673A (en) | Compounds and their use | |
ZA9100132B (en) | Lipid-selective antioxidants and their preparation and use | |
EP0894807A4 (en) | GPIb-LIPID COMPLEX AND USES THEREOF | |
HU9501329D0 (en) | Novel 3,3-diphenylpropylamines, their use and preparation | |
HK1023571A1 (en) | Thienotriazolodiazepine compounds and medicinal use thereof | |
IL115493D0 (en) | Cycloalkano-indole and azaindole derivatives their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |